M/s. Mylan Pharmaceuticals Inc, Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: M/s. Mylan Pharmaceuticals Inc, Pharmaceutical Import Records from India — 9 Products, $8.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Mylan Pharmaceuticals Inc, — Pharmaceutical Importer Profile (2026) | 9 Products, $8.0M Trade | TransData Nexus

M/s. Mylan Pharmaceuticals Inc,

Pharmaceutical Importer · United States · Gastrointestinal Focus · $8.0M Total Trade · DGFT Verified

M/s. Mylan Pharmaceuticals Inc, is a pharmaceutical importer based in United States with a total trade value of $8.0M across 9 products in 7 therapeutic categories. Based on 159 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. Mylan Pharmaceuticals Inc, sources from 3 verified Indian suppliers, with Mylan Laboratories Limited accounting for 96.9% of imports.

M/s. Mylan Pharmaceuticals Inc, — Import Portfolio & Supplier Network

M/s. Mylan Pharmaceuticals Inc, import network — 9 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. Mylan Pharmaceuticals Inc,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$12.1M	310	96.9%
Usv Private Limited	$200.0K	4	1.6%
Unichem Laboratories Limited	$184.9K

What Formulations Does M/s. Mylan Pharmaceuticals Inc, Import?

Formulation	Value	Ships
Pantoprazole sodium delayed-release	$1.2M	26
Metformin hydrochloride tablets USP	$700.0K	14
Valsartan and hydrochlorothiazide	$550.0K	11
Pantoprazole sodium delayed release	$518.2K	11
Metoprolol succinate extended release	$368.0K	11
Atorvastatin calcium tablets USP 20 MG	$350.0K	7
Amlodipine and valsartan tablets USP 5MG	$342.4K	7
Potassium chloride extended-release	$275.6K	6
Lansoprazole delayed release capsules	$223.6K	7
Valacyclovir tablets USP 500 MG 90bt	$200.0K	4
Atorvastatin calcium tablets USP 80 MG	$200.0K	4
Atovaquone and proguanil hydrochloride	$200.0K	4
Atorvastatin calcium tablets USP 40 MG	$200.0K	4
Lithium carbonate extended release	$191.2K	4
Amlodipine and valsartan tablets USP	$183.8K	4

M/s. Mylan Pharmaceuticals Inc, imports 140 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 9 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pantoprazole	Gastrointestinal	$1.9M	37	0.1%	14
2	Sodium	Nutritional Supplements	$1.9M	37	0.5%	18
3	Valsartan	Cardiovascular	$1.6M	31	0.8%	9
4	Hydrochlorothiazide	Diuretics	$600.0K	12	0.1%	13
5	Acyclovir	Antivirals	$550.0K	11	0.4%	5
6	Valacyclovir	Antivirals	$550.0K	11	0.6%	4
7	Diazepam	CNS & Psychiatric	$500.0K	10	6.7%	3
8	Atovaquone	Antimalarial & Antiparasitic	$250.0K	5	0.0%	11
9	Proguanil	Antimalarial & Antiparasitic	$250.0K	5	0.0%	4

M/s. Mylan Pharmaceuticals Inc, imports 9 pharmaceutical products across 7 categories into United States totaling $8.0M.

M/s. Mylan Pharmaceuticals Inc, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Pharmaceuticals Inc. is a prominent pharmaceutical company based in the United States, specializing in the importation and distribution of finished pharmaceutical formulations. Established in 1961, Mylan has evolved into a significant player in the global pharmaceutical industry, focusing on providing access to a wide range of generic and specialty medicines. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris Inc., a global healthcare company.

Headquartered in Canonsburg, Pennsylvania, Viatris operates through various subsidiaries, including Mylan Pharmaceuticals Inc., which continues to play a crucial role in the importation and distribution of pharmaceutical products within the United States. The company's extensive portfolio encompasses a diverse array of therapeutic categories, reflecting its commitment to addressing a broad spectrum of medical needs. Viatris's operations span multiple continents, including North America, Europe, Asia, and Latin America, underscoring its global reach and influence in the pharmaceutical sector.

2Distribution Network

Viatris, through its subsidiary Mylan Pharmaceuticals Inc., maintains a robust distribution network across the United States, ensuring efficient delivery of pharmaceutical products to various healthcare providers and institutions. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are designed to support a wide geographic coverage, facilitating timely and reliable distribution. This extensive network enables Viatris to serve a diverse customer base, including retail pharmacies, hospitals, and government agencies, thereby reinforcing its position in the U.S. pharmaceutical market.

3Industry Role

Mylan Pharmaceuticals Inc. operates as a pharmaceutical importer and distributor within the United States, focusing on the importation of finished pharmaceutical formulations from various global suppliers, including India. The company's role in the U.S. pharmaceutical supply chain involves sourcing a wide range of generic and specialty medicines, which are then distributed to healthcare providers, pharmacies, and other stakeholders. By leveraging its global sourcing capabilities, Mylan Pharmaceuticals Inc. contributes to enhancing the accessibility and affordability of essential medications across the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. Mylan Pharmaceuticals Inc,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Pharmaceuticals Inc. demonstrates a significant concentration in its sourcing strategy, with a substantial portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations totaling $8.0 million USD from India, encompassing 159 shipments across nine products in seven therapeutic categories. The top five imported products include Pantoprazole, Sodium, Valsartan, Hydrochlorothiazide, and Acyclovir, collectively accounting for 80.5% of the total import value. This high concentration indicates a strategic reliance on specific suppliers and products, which can offer benefits such as cost efficiency and streamlined supply chain management. However, it also introduces potential risks related to supply chain disruptions, currency fluctuations, and geopolitical factors that could impact the stability and continuity of supply.

The shipment data reveals a stable relationship with key Indian suppliers, notably Mylan Laboratories Limited, which accounts for 96.9% of the total import value. This consistent sourcing pattern suggests a well-established and reliable partnership. Nonetheless, the limited number of suppliers (three unique suppliers) and the high concentration in the top five products may expose Mylan Pharmaceuticals Inc. to vulnerabilities in the event of supply chain disruptions or changes in supplier dynamics. Diversifying the supplier base and product portfolio could mitigate these risks and enhance the resilience of the company's sourcing strategy.

2Supply Chain Resilience

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA's mission is to protect public health by ensuring that drugs imported into the U.S. meet standards for quality, safety, and effectiveness. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation of drugs, including requirements for registration, listing, and compliance with labeling standards.

For Indian pharmaceutical exporters, understanding the FDA's regulations is crucial for successful market entry. The FDA requires foreign drug establishments to register their facilities and list all drug products intended for import into the U.S. This process involves submitting an entry notice and an entry bond to U.S. Customs and Border Protection (CBP), pending FDA's decision regarding the admissibility of the product. FDA reviews imported drugs to determine their compliance with U.S. standards, and products may be refused entry if they are found to be adulterated, misbranded, or unapproved.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Foreign drug establishments must register with the FDA and list all drug products intended for import. This registration process ensures that imported drugs meet U.S. standards for quality, safety, and effectiveness. Good Manufacturing Practice (GMP) certification is a critical component of this process. The FDA recognizes GMP certifications from various international bodies, including the World Health Organization (WHO), the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and the European Union (EU). For Indian exporters, obtaining WHO-GMP certification is particularly relevant, as it aligns with FDA expectations and facilitates smoother market entry.

M/s. Mylan Pharmaceuticals Inc, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Pharmaceuticals Inc.'s product strategy focuses on importing finished pharmaceutical formulations across a diverse range of therapeutic categories, including gastrointestinal, nutritional supplements, and cardiovascular medications. The company's import portfolio reflects a strategic emphasis on high-demand therapeutic areas, with the top three categories—gastrointestinal, nutritional supplements, and cardiovascular—each accounting for 23.3%, 23.3%, and

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — M/s. Mylan Pharmaceuticals Inc,

What products does M/s. Mylan Pharmaceuticals Inc, import from India?

M/s. Mylan Pharmaceuticals Inc, imports 9 pharmaceutical products across 7 categories. Top imports: Pantoprazole ($1.9M), Sodium ($1.9M), Valsartan ($1.6M), Hydrochlorothiazide ($600.0K), Acyclovir ($550.0K).

Who supplies pharmaceuticals to M/s. Mylan Pharmaceuticals Inc, from India?

M/s. Mylan Pharmaceuticals Inc, sources from 3 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (96.9% of imports, $12.1M).

What is M/s. Mylan Pharmaceuticals Inc,'s total pharmaceutical import value?

M/s. Mylan Pharmaceuticals Inc,'s total pharmaceutical import value from India is $8.0M, based on 159 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. Mylan Pharmaceuticals Inc, focus on?

M/s. Mylan Pharmaceuticals Inc, imports across 7 categories. The largest: Gastrointestinal (23.3%), Nutritional Supplements (23.3%), Cardiovascular (19.5%).

Get Full M/s. Mylan Pharmaceuticals Inc, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.